[The variable course of pulmonary histiocytosis X].
The authors report on the course seen in 7 cases of pulmonary histiocytosis X. In Group I (3 patients) immunosuppressive therapy was initiated on account of severe general symptoms and reduced pulmonary function. Remission was induced in 2 cases, whereas relapses occurred intermittently in one patient. In Group II without general symptoms and largely normal pulmonary function the course was only monitored. Progression did not occur with any of the patients. Pulmonary histiocytosis X should be treated with corticosteroid monotherapy in case of progressive deterioration of pulmonary function and/or if there are severe general symptoms. Chance findings in patients who are otherwise free from complaints should merely result in a closely meshed control checkup before taking any action.
Fischer
B M
BM
III. Medizinische Klinik-Schwerpunkt Pneumologie, Johannes Gutenberg-Universität, Mainz.
Schadmand
S
S
Schlegel
J
J
D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D007166:Immunosuppressive Agents